Patients with systemic amyloidosis should be considered at increased risk of complications and mortality in case of SARS-CoV2 infection. This may be particularly relevant for patients with heart involvement,because subjects with SARS-CoV2 infection and preexisting cardiovascular disease have an increased risk of severe clinical manifestations and death, the infection has been associated with cardiovascular complications, and therapies under investigation for COVID-19 may have cardiovascular side effects. 

Read the full paper published by the International Society of Amyloidosis >>